We’re super excited to share that Sara Morren has been promoted to Chief of Staff to the Managing Partner! Sara has been with us for six years, growing from her role as HR Manager and Personal Assistant into someone who’s become absolutely essential to how we work and move forward as a team. Anyone who’s worked with her knows how sharp, driven, and supportive she is. She brings clarity, structure and efficiency – no matter how complex things get. This new title is really just catching up with reality – Sara has already been playing this key role at the center of our organization. Whether it’s connecting the dots, keeping things (and people) on track, or making sure no ball gets dropped, she’s the steady hand behind the scenes. We figured that calling her a “jack-of-all-trades” or our “first point of contact” didn’t quite do her justice – so Chief of Staff it is. 😉 Big congrats, Sara – can’t wait to see what’s next! 🙌 #TeamUpdate #Promotion #ChiefOfStaff #Congrats #Leadership #CareerGrowth
Droia Ventures
Directeurs du capital-risque et du capital-investissement
Droia is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic disease.
À propos
Droia is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic disease. Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients. With our team of seasoned scientists, entrepreneurs and investment professionals we build great companies to save patients’ lives. More information can be found on www.droiaventures.com.
- Site web
-
http://www.droiaventures.com
Lien externe pour Droia Ventures
- Secteur
- Directeurs du capital-risque et du capital-investissement
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Zaventem
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2011
- Domaines
- Invest, Biopharma, Oncology et Genetic Diseases
Lieux
-
Principal
Da Vincilaan 1
1930 Zaventem, BE
Employés chez Droia Ventures
Nouvelles
-
We’re excited that Droia Ventures is sponsoring Bio€quity Europe this year — especially in the charming setting of our home country, with the event taking place in the historic city of Bruges from May 12 to 14. Celebrating its 25th year, Bio€quity Europe (BioCentury Inc.) is the destination event for biopharma decision-makers to network, partner and debate critical issues facing the biotech industry. Join Matthias Van Woensel, Mathias Declercq , and Lawrence Van Helleputte during the Welcome Reception, co-hosted by Droia, on Monday evening at 8 PM on Bruges’ iconic Main Square as we raise a glass to celebrate 25 years of Bio€quity Europe! #BioEquityEurope2025 #Biotech #InformaConnect #LifeSciences #Healthcare #Bruges #Flanders #Belgium
-
-
We are excited to share that Lawrence Van Helleputte, Associate at Droia Ventures, will be attending the upcoming PNS (Peripheral Nerve Society) Conference in Edinburgh, taking place from May 17th to 20th, 2025. The PNS Conference brings together leading scientists, clinicians, and industry professionals dedicated to advancing research and therapies related to the peripheral nervous system. Lawrence looks forward to engaging with innovators and researchers at the forefront of this field, exploring new scientific insights, and discussing potential opportunities for collaboration. If you’re attending the conference and would like to connect, feel free to reach out Lawrence Van Helleputte! #PNS2025 #PeripheralNeuropathy #Symposium #GrowingTogether
-
-
We are pleased to announce that our colleagues Matthias Van Woensel, Partner at Droia Ventures and Mathias Declercq, Senior Associate, will be attending the prestigious AACR 2025, American Association for Cancer Research, Chicago next month. ✨ Looking ahead to AACR 2025 – where science meets impact! Let’s push the boundaries of innovation — together. 💡🧬 #CancerResearch #Innovation #Collaboration #AACR2025 #AACR #cancer #cancerresearch #drugdevelopment #healthcare
-
-
Droia Ventures a republié ceci
We are pleased to introduce Hillstar Bio, a pioneering biotechnology company dedicated to transforming the treatment of autoimmune diseases. Today, we launched with a $67 million Series A financing led by a syndicate of experienced investors and shareholders from the U.S., Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings, LifeArc Ventures, and Hummingbird Bioscience. Developed by a world-class team of experts, Hillstar’s approach targets and depletes pathogenic immune cells while preserving healthy ones. We aim to reset the immune system and provide patients with durable therapeutic responses, potentially reducing the need for long-term immunosuppressive treatments. Learn more about Hillstar Bio here: https://bit.ly/4iYfiBi #hillstarbio #precisionimmunotherapy #precisionimmunology #autoimmunedisease #immunology #trbv9 #invisibleillness #chronicillness #axspa
-
-
🌟 Another proud moment at Droia Labs / Metaptys! 🌟 We’re thrilled to share that Kathleen Sonck has been promoted to Principal Scientist! Since joining us in 2022, Kathleen Sonck has stood out through her independence, quick grasp of complex topics, and her consistently positive and proactive mindset. No task is ever too small, she tackles everything with energy and a can-do attitude. This promotion is a reflection of her outstanding contribution to the team and her continued growth as a scientist and leader. Huge congratulations, Kathleen Sonck — here’s to the next chapter! 🚀👏 #TeamMetaptys #DroiaLabs #LifeSciences #Promotion #Leadership #ScientificExcellence #WomenInSTEM
-
-
🎉 Exciting news from Droia Labs / Metaptys! 🎉 We’re proud to announce the promotion of Katleen Brepoels to Senior Technician! Katleen has been with us since the very beginning of Droia Labs in 2022, and her journey has been nothing short of impressive. Her growing independence and initiative in taking on valuable and complex research projects have truly set her apart. This new title is a well-deserved recognition of her dedication, expertise, and continuous growth. Congratulations, Katleen Brepoels — we’re lucky to have you on the team! 👏 #TeamMetaptys #DroiaLabs #LifeSciences #Promotion #CareerGrowth #Gratitude #Teamwork
-
-
Mathias De Decker, our Senior Scientific Analyst at Droia, will be attending the prestigious Annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) 🧠💡 in Vienna 🇦🇹, taking place from April 1-5. The AD/PD conference is a key event in the field of neurodegenerative diseases, bringing together leading experts, researchers, and professionals with a shared goal of striving for a better future for those affected by Alzheimer’s, Parkinson’s, and related neurological disorders. Mathias is eager to connect 🤝, exchange insights 📚, and contribute 🔍 to the ongoing efforts to combat these diseases. We are excited for the valuable insights that will emerge from this important gathering and look forward to the continued progress in the fight against neurodegenerative disorders! 🚀🌍 #ADPD2025 #Neuroscience #Innovation
-
-
We are thrilled to share that as of March 1st, Dieter Petit, PhD Petit has been promoted to Senior Associate! 🎉 Dieter has been an invaluable member of our team, bringing sharp insights, dedication, and a true passion for science. His contributions have been instrumental in driving Droia’s mission forward! Congratulations, Dieter! Well deserved! 👏 #DroiaVentures #Promotion #TeamGrowth #BiotechInvesting
-
-
Thrilled to announce that our Associate, Dieter Petit, PhD will attend @BioEurope Spring 2025 in Milan from March 17-19! 🇮🇹✨ This event is always a great opportunity to connect with fellow investors, pharma leaders, and biotech innovators, exchanging insights on the latest industry trends and opportunities. If you’re attending, let’s connect on-site and explore ways to collaborate! 🤝 #BioEuropeSpring #Biotech #Pharma #Investment #Networking #LifeSciences #Milan2025
I'm attending the BioEurope Spring 2025 event in Milan from 17-19 March. Looking forward to connect on site with colleague investors, pharma and biotech companies.
-